[(18)FDG PET/CT imaging in primary breast lymphoma and breast cancer].
BACKGROUND
Of women between 15 and 29 years of age, 13.6% will die from breast cancer. For women between 30 and 64 years of age, 19% will die from breast cancer.


METHODS
We studied 1728 oncological patients and 295 patients were included, 293 with breast cancer (17%) and two patients with primary breast lymphoma (0.1%).


RESULTS
There were 98% females and 2% males. SUVmax for the primary tumor was 4.2 +/- 2.6 SD. Mean SUVmax for patients with primary breast lymphoma were 3.2 and 1.4. Sites of metastases were lymph nodes in the neck (4.4% SUVmax 2.7), internal mammary lymph nodes (5% SUVmax 5.3), mediastinum (8.3% SUVmax 5.0), retroperitoneal (6 % SUVmax 5.4), ipsilateral axilla (94% SUVmax 4.5), contralateral axilla (4.4% SUVmax 2.8), pectoral muscle (10.2% SUVmax 2.6), pleura (4.4% SUVmax 3.9), lung (32.3% SUVmax 2.9), liver (19.1% SUVmax 4.5), bone (36.7%), adrenal gland (4.4% SUVmax 2.4), brain (4.4%), spleen and contralateral breast, one case each. One patient presented thymic hyperplasia after chemotherapy. Mean SUVmax for blastic lesions was 5.4 +/- 2.9 SD, for lytic lesions it was 6.7 +/- 2.4 SD and for lesions not apparent on the CT it was 4.6 +/- 2.4 SD. The incidence of a second primary was 4.7%, 2.1% ovarian, 1.4% lung, 0.3% lymphoma, 0.3% endometrium, 0.3% pancreas and 0.3% thyroid.


CONCLUSIONS
Mean SUVmax for the primary tumor was similar to that reported in the literature. Values for metastatic bone lesions are higher in this study. Inclusion of PET/CT in the followup of breast lesions is cost efficient.
Estrada-Sánchez
Gisela
G
CT Scanner del Sur, México, D.F. dragiselaus@yahoo.com
Ochoa-Carrillo
Francisco Javier
FJ
Altamirano-Ley
Javier
J
D000328:Adult; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000453:epidemiology; D018567:Breast Neoplasms, Male / Q000000981:diagnostic imaging; D002277:Carcinoma / Q000000981:diagnostic imaging*; D003362:Cost-Benefit Analysis; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D006965:Hyperplasia; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging; D008297:Male; D008327:Mammography; D009378:Neoplasms, Multiple Primary / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography / Q000191:economics; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D013950:Thymus Gland / Q000000981:diagnostic imaging / Q000473:pathology; D014057:Tomography, X-Ray Computed
D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18